sábado, 15 de agosto de 2009

Escitalopram and Sertraline Are More Efficacious and Acceptable Than Ten Other New-Generation Antidepressants

This is the Medscape Psychiatry Minute. I'm Dr Peter Yellowlees. Many second-generation antidepressants are now available to treat major depression, but how do we compare them for efficacy and acceptability? Nine investigators[1] from Oxford, England, and Verona, Italy, report in the Lancet in 2009a multiple-treatment meta-analysis of 117 randomized controlled trials that used 12 second-generation antidepressants in 25,928 participants with unipolar major depression. The main outcomes were the proportion of patients who responded to, or dropped out of, the allocated treatment, and analysis was done on an intention-to-treat basis. The authors concluded that there were clinically important differences among the 12 antidepressants for both efficacy and acceptability in favor of escitalopram and sertraline. They noted that sertraline, one of the early second-generation antidepressants, had the most favorable overall balance between benefits, acceptability, and cost. This article is selected from Medscape Best Evidence
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373 :746-758
Psychiatry Best Evidence, powered by McMaster Plus. Available at: http://www.medscape.com/pages/features/newsletters/bestevidence/psychiatry
Authors and Disclosures, Author(s):
Peter Yellowlees, MBBS, MD
Professor of Psychiatry, University of California Davis, Sacramento, California; Director, Health Informatics Graduate Program, University of California Davis, Sacramento, California
Disclosure: Peter Yellowlees, MBBS, MD, has disclosed no relevant financial relationships.

No hay comentarios:

Publicar un comentario